Teladoc (TDOC) Gets $7 Price Target: Can It Double?
Barclays has set a $7 price target on Teladoc as the company eyes growth from BetterHelp's insurance transition and s...
Retirees benefit from selecting tax-efficient asset classes and optimized withdrawal sequencing. Learn which classes to favor and why.
23,930 articlesBarclays has set a $7 price target on Teladoc as the company eyes growth from BetterHelp's insurance transition and s...
When a beloved artist leans into a high-profile relationship, questions rise about independence and money. This guide...
The U.S. economy grew at a 2.0% annualized rate in Q1, powered by AI-related investment and resilient consumer spendi...
Ted Turner's launch of CNN and the dawn of nonstop coverage reshaped investing and budgeting for households. This pie...
MIAX is shaping 2026 in a dynamic way, and the first-quarter earnings transcript offers clues about growth drivers an...
BigBear.AI delivers a stronger Q1 2026, expanding margins and backlog while signaling a ramp in defense contracts. Th...
A breakthrough approval can move a biotech stock in dramatic ways. This guide breaks down how to assess the upside, m...
As PacBio lays out its Q1 2026 results, investors hunt for catalysts, cadence, and cash runway signals. This guide tr...
Axsome Therapeutics stock keeps climbing, hitting another high as regulatory news and a solid quarterly update bolste...
What could happen to NuScale Power stock over the next five years? This article breaks down the catalysts, scenarios,...
Circle Internet Group posted a stronger-than-expected Q1 2026, triggering a 68% year-to-date gain and a rally that ou...
Analysts are watching every cue as Apple navigates leadership shifts and growth bets. This article breaks down what a...